Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (151-160 of 327) with videos related to

Pageof 33
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanomaRichard W Joseph, Ryan J Sullivan, Robyn Harrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid TumorsRandy F Sweis, Georgina V Long, Adil Daud, et al.
Thyroid : Official Journal of the American Thyroid Association|January 31, 2018
Circulating BRAF<sup>V600E</sup> Levels Correlate with Treatment in Patients with Thyroid CarcinomaCarrie C Lubitz, Tiannan Zhan, Viswanath Gunda, et al.
Science Advances|June 24, 2021
Rejection of benign melanocytic nevi by nevus-resident CD4<sup>+</sup> T cellsErik B Schiferle, Se Yun Cheon, Seokjin Ham, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapyNaiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, et al.
Nature Communications|October 16, 2021
Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanomaKuang Du, Shiyou Wei, Zhi Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2025
Circulating tumor DNA is prognostic of patient outcome and enables therapy monitoring in metastatic uveal melanomaEgle Ramelyte, Julian Kött, Aleigha R Lawless, et al.
Journal of Vascular and Interventional Radiology : JVIR|December 23, 2020
Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety AnalysisKonstantin S Leppelmann, Meghan J Mooradian, Suvranu Ganguli, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2022
Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitorsZsofia D Drobni, Olivier Michielin, Thiago Quinaglia, et al.
Pageof 33

Showing results (151-160 of 327) with videos related to

Sort By:
Pageof 33
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanomaRichard W Joseph, Ryan J Sullivan, Robyn Harrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Lipid Nanoparticle-encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ Plus Durvalumab Induces an Immunostimulatory Effect Within the Tumor Microenvironment in Patients with Advanced Solid TumorsRandy F Sweis, Georgina V Long, Adil Daud, et al.
Thyroid : Official Journal of the American Thyroid Association|January 31, 2018
Circulating BRAF<sup>V600E</sup> Levels Correlate with Treatment in Patients with Thyroid CarcinomaCarrie C Lubitz, Tiannan Zhan, Viswanath Gunda, et al.
Science Advances|June 24, 2021
Rejection of benign melanocytic nevi by nevus-resident CD4<sup>+</sup> T cellsErik B Schiferle, Se Yun Cheon, Seokjin Ham, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapyNaiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, et al.
Nature Communications|October 16, 2021
Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanomaKuang Du, Shiyou Wei, Zhi Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2025
Circulating tumor DNA is prognostic of patient outcome and enables therapy monitoring in metastatic uveal melanomaEgle Ramelyte, Julian Kött, Aleigha R Lawless, et al.
Journal of Vascular and Interventional Radiology : JVIR|December 23, 2020
Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety AnalysisKonstantin S Leppelmann, Meghan J Mooradian, Suvranu Ganguli, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2022
Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitorsZsofia D Drobni, Olivier Michielin, Thiago Quinaglia, et al.
Pageof 33